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Abstract
Vascular and metabolic diseases cause half of total mortality in Europe. New prognostic markers would provide a valuable
tool to improve outcome. First evidence supports the usefulness of plasma lipid species as easily accessible markers for
certain diseases. Here we analyzed association of plasma lipid species with mortality in the Ludwigshafen Risk and
Cardiovascular Health (LURIC) study. Plasma lipid species were quantified by electrospray ionization tandem mass
spectrometry and Cox proportional hazards regression was applied to assess their association with total and cardiovascular
mortality. Overall no differences were detected between total and cardiovascular mortality. Highly polyunsaturated
phosphatidylcholine species together with lysophosphatidylcholine species and long chain saturated sphingomyelin and
ceramide species seem to be associated with a protective effect. The predominantly circulating phosphatidylcholine-based
as well as phosphatidylethanolamine-based ether species and phosphatidylethanolamine species were positively associated
with total and cardiovascular mortality. Saturated and monounsaturated phosphatidylcholine species, especially
phosphatidylcholine 32:0 (most probably dipalmitoyl-phosphatidylcholine) and palmitate containing sphingomyelin and
ceramide species showed together with 24:1 containing sphingomyelin and ceramide species strongest positive association
with mortality. A quotient of the sums of the six most protective species and the six species with the strongest positive
mortality association indicated an almost 3-fold increased risk of mortality, which was higher than the hazard ratio for
known risk factors in our cohort. Plasma lipid species levels and especially ratios of certain species may be valuable
prognostic marker for cardiovascular and total mortality.
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Introduction
Vascular and metabolic diseases represent a major challenge in
healthcare in Europe, causing almost half of total mortality [1].
Major non-changeable risk factors are age, gender and heredity.
They stand in contrast to modifiable risk factors like hypertension,
metabolic overload, physical inactivity, obesity, low high density
lipoprotein (HDL) cholesterol and/or high triglycerides (TG)
which cluster in the metabolic syndrome or type 2 diabetes
mellitus. It is suggested that obesity related metabolic diseases like
type 2 diabetes mellitus and its major endpoint cardiovascular
disease are the result of a common molecular mechanism marked
by two independent mechanisms: 1) selective insulin resistance
(IR), and 2) lipotoxicity [2].
Identification of plasma lipid species associated with diseases
provided first evidence for their usefulness as easily accessible
markers, improving diagnosis and treatment. Recently more than
500 lipids species constituting the main lipid classes have been
quantified in human plasma. These data may serve as base for
additional studies to analyze their role in health and disease [3].
Initial data indicate that lipid profiling may be helpful to reveal
certain diseases like e.g. type 1 diabetes [4], non-alcoholic fatty
liver disease [5] and that plasma sphingomyelin (SM) and
ceramide (Cer) may be used as potential biomarkers for
Alzheimers disease [6]. Furthermore they may be used not only
to identify clinical endpoints but also intermediate stages [7].
Zwitterionic phosphatidylcholine (PC) and phosphatidyletha-
nolamine (PE) are the two main phospholipids in eukaryotic cells.
PC is also a major component of several secretory products like
HDL, bile, and pulmonary surfactant [8]. Enzymatic hydrolysis of
one fatty acid (FA) mainly by phospholipase A2 activity leads to
Lyso-PC (LPC) species formation, acting as highly abundant
signaling molecules through specific G protein-coupled receptors
[9]. A recent study revealed associations of phospholipase A2,
LPC, lysophosphatidic acid and proinflammatory cytokine levels
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in atherosclerotic plaques, suggesting involvement of LPC in
plaque inflammation and vulnerability [10].
It was shown recently that total PC and TG are elevated in
hypertensive patients and that antihypertensive agents reduce
plasma total cholesteryl esters and TG [11]. Obesity leads to
increased lipid load in plasma, while IR controlled for body mass
index (BMI) has little effects on plasma lipid composition. In
hypertension ether lipids, especially arachidonic (20:4) and
docosapentaenoic (22:5) acid containing PCs and PEs, were found
reduced [12]. Arachidonic and docosapentaenoic acid are
essential FAs generated from linoleic and a-linolenic acid by
desaturation mediated by the fatty acid desaturases 2 (FADS2) and
1 (FADS1) and elongation through ELOVL fatty acid elongase 5
(ELOVL5). A common finding is the association of members of
the FADS gene cluster (FADS1-3) with phospholipid and FA
species and their chain length and degree of saturation [13–15].
FADS1 catalyses delta-5 desaturation (D5D), converting eicosa-
trienoyl-CoA (20:3) to arachidonyl-CoA (20:4). These FAs are
found for example in PC 36:3 and PC 36:4 and the ratio between
PC 36:3 and 36:4 is regarded as a good predictor of the FADS1/
D5D activity [13]. Furthermore several additional loci associated
with phospholipid species were identified, among those key
enzymes involved in lipid metabolic processes like beta oxidation,
polyunsaturated FA (PUFA) synthesis, TG breakdown and
receptor-mediated lipoprotein uptake [13,15]. An overview of
published SNP-lipid species correlations related to vascular and
metabolic disease was recently published [16]. The FADS cluster
is also associated to SM species formation, where FA chain length
and desaturation determine substrate specificity for Cer-synthases
regulating the FA composition of Cer [17] from which SM is
generated. Sphingolipids are localized in cell and organelle
membranes and lipoproteins and are suggested to exert important
functions in cell signaling, cell surface protection, protein and lipid
transport and sorting. Recent publications highlight their roles in
both health and disease including cardiovascular disease [18,19].
In the EUROSPAN study the FADS cluster and FA specific genes
involved in Cer metabolism, namely ceramide synthase 4
(CERS4/LASS4), sphingosine-1-phosphate phosphatase 1
(SGPP1), and serine palmitoyltransferase, long chain base subunit
3 (SPTLC3), were identified as polymorphic genes that correlate
with sphingolipid species in plasma [14]. Cer occupies the central
position in sphingolipid metabolism. It is either derived from the
breakdown of complex sphingolipids via the ‘‘salvage pathway’’ or
from ‘‘de novo synthesis’’ at the cytosolic surface of the
endoplasmatic reticulum. De novo Cer synthesis shows pro-
nounced specificity for the saturated long chain FAs palmitate
(16:0) and stearate (18:0) [20]. Both, palmitate and stearate, have
been shown to induce apoptosis in cultured cells [21–23] and part
of cardiomyocyte loss in genesis or progression of heart failure in
humans is mediated by apoptosis [24]. As FA-induced apoptosis is
specific for these two FAs [22] it has been suggested that FA-
induced apoptosis is mediated by Cer synthesis. While this appears
to be true for some cell types [22,23] other data indicate that Cer is
not causal for FA-induced apoptosis [25] but may enhance the
effect [25]. Cer, IR and inflammation are suggested to be linked
via an IL-6 related mechanism. Cer may also influence induction
of inflammation that is involved in IR states that are often found
with coronary heart disease [26]. Furthermore elevated plasma
Cer levels were found to be correlating with hypertension grade
[27]. High human plasma SM levels showed association with
coronary artery disease (CAD) [28].
Previously, free FA levels were identified as independent
predictors of total and cardiovascular mortality and as indepen-
dent risk factors for future sudden cardiac death in the
Ludwigshafen Risk and Cardiovascular Health (LURIC) study
[29,30]. Here we analyzed the association of various plasma lipid
species with mortality in the LURIC study. We focused on the
analysis of glycerophospholipids, namely PC, LPC, PC O, PE and
PE O and two sphingolipids, SM and Cer.
Materials and Methods
Study design and participants
The LURIC study design has been described [31]. In brief it
included patients of Caucasian origin hospitalized for coronary
angiography between June 1997 and May 2001. The study was
approved by the ethics review committee at the ‘‘Landesa¨rzte-
kammer Rheinland-Pfalz’’ (Mainz, Germany). Written informed
consent was obtained from each of the participants. Clinical
indications for angiography were chest pain or non-invasive tests
consistent with myocardial ischemia. To limit clinical heterogene-
ity, individuals suffering from acute illness other than acute
coronary syndromes, chronic non-cardiac diseases and a history of
malignancy within the five past years were excluded. Criteria for
the definition of CAD were recently published [32]. Anthropo-
metric and clinical parameters of the examined cohort were
previously published [33] and a short summary is shown in table 1.
Lipidomics
Plasma lipid species were quantified by electrospray ionization
tandem mass spectrometry (ESI-MS/MS) as previously published
[34–36]. A precursor ion scan of m/z 184 specific for phosphocho-
line containing lipids was used for PC, LPC and SM [34,36]. Cer
was analyzed using a fragment ion of m/z 264 [35]. For each lipid
class two non-naturally occurring internal standards were added
and quantification was achieved by calibration lines generated by
addition of naturally occurring lipid species to plasma. Deisotoping
and data analysis for all lipid classes was performed by self
programmed Excel Macros according to the principles described
previously [34]. Lipid species were annotated according to the
‘‘Shorthand Notation for Lipid Structures Derived from Mass
Spectrometry’’ [37]. Glycerophospholipid species were annotated
based on assumption of even numbered carbon chains only. SM
Table 1. Anthropometric and clinical parameters of the
examined cohort.
Age (years) 62.7 (610.6)
BMI (kg/m2) 27.5 (64.1)
LDL cholesterol (mg/dL) 116.6 (634.3)
HDL cholesterol (mg/dL) 38.7 (610.8)
Triglycerides (mg/dL) 147 (109 – 201)
Mean systolic blood pressure (mmHg) 141.1 (623.6)
Mean diastolic blood pressure (mmHg) 81.0 (611.5)
Mean fasting glucose (mg/dL) 113.4 (635.4)
Male gender 69.7%
CAD (.10% or clinical) (yes/no) 77.9%
CAD 50% or more visual stenosis (yes/no) 67.3%
Diabetics (yes/no) 32.1%
Hypertension (yes/no) 72.7%
Smoking (no/ex(.30d)/active) 35.5%/41.0%/23.4%
BMI, body mass index; CAD, coronary artery disease; HDL, high density
lipoprotein; LDL, low density lipoprotein.
doi:10.1371/journal.pone.0085724.t001
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species annotation is based on the assumption that d18:1
(dihydroxy 18:1 sphingosine) is the main base of plasma SM
species.
Statistical analysis
All lipid variables were logarithmically transformed and divided
by their respective standard deviation to achieve a normal
distribution prior to analyses. Cox proportional hazards regression
was applied to assess the effect of molecular lipids on total and
cardiovascular mortality during a median follow-up of 8 years.
The six molecular lipid species which showed the strongest
protective effect and the six molecular lipid species that showed the
highest risk increment were summed up to create a protective
lipids score and a risk lipids score, respectively. We then calculated
the ratio of risk lipids to protective lipids and assessed the
association with mortality per 0.1 unit increase of the ratio by Cox
regression analysis. Models were adjusted for age, gender,
smoking, low density lipoprotein (LDL), HDL, diabetes and
hypertension. Two-sided P-values ,0.05 were used to indicate
statistical significance. The SPSS statistical package version 16.0
for Windows was used for all analyses.
Results
We applied ESI MS/MS to analyze the lipid species of PC,
LPC, PE, SM and Cer in plasma of 3316 subjects from the
LURIC study.
38 PC, 15 LPC, 30 PC O, 31 PE, 24 PE O, 33 SM and 7 Cer
species were detected and associated with total (n = 768) and
cardiovascular (n = 484) mortality. Models were adjusted for age,
gender, smoking, LDL, HDL, diabetes and hypertension. Our
cohort included 733 controls and 2583 CAD positive patients.
From the 2583 patients 1368 had survived a myocardial infarction
prior to enrollment in the study. The CAD group was significantly
older than the control group, showing significantly higher
prevalence for type 2 diabetes, smoking, and hypertension. They
also had significantly higher TG levels, while HDL and LDL (due
to more patients with CAD taking statins) levels were found
reduced.
Altogether 19 PC species (Figure 1A), 3 LPC species (Figure 1B),
7 PC O (Figure 1C), 17 PE species (Figure 2A), 5 PE O (Figure 2B),
9 SM species (Figure 3A) and 5 Cer species (Figure 3B) were found
significantly associated with total and/or CAD mortality. All
identified species were similarly associated with total and CAD
mortality (Figure 1–3). Among the identified 19 PC species 9 were
positively associated with mortality; three saturated species (PC
30:0, 32:0, 38:0), four monounsaturated species (PC 30:1, 32:1,
34:1, 36:1) and two polyunsaturated species (PC 34:2, 38:2)
(Figure 1A). PC 32:0 showed the strongest positive mortality
association. Interestingly PC 32:1 and PC 32:2 diminish their
mortality association with PC 32:2 being even slightly, but
significantly protective (Figure 1A). In contrast to PC 32:2, PC
34:2 and PC 38:2 did not display any protective effect, although a
trend towards lower mortality association compared to their
saturated/monounsaturated counterparts is visible. Against this
trend PC 30:1 revealed even stronger mortality association than
PC 30:0. Among the PC 38 species, six desaturation products
ranging from PC 38:2 - PC 38:7 were identified. While PC 38:0
and PC 38:2 were found significantly associated with mortality PC
38:3 - PC 38:7 were all significantly associated with a protective
effect (Figure 1A). A significant association with a protective effect
was also visible for PC 36:4, PC 36:5, PC 40:6 and PC 40:7. All
protective PC species showed overall a slightly higher assocition
with death due to CAD than to total mortality. Three LPC species
were identified (16:0, 18:0, 18:2) which were all found associated
with a protective effect (Figure 1B). All 7 identified PC O species
revealed positive mortality association (Figure 1C); two saturated
species (PC O-32:0, PC O-34:0), two monounsaturated species
(PC O-32:1, PC O-34:1) and three unsaturated species (PC O-
34:3, PC O-38:5, PC O-40:5). Similar to PC 32:0, PC O-32:0
showed strongest positive mortality association while mortality
association of PC O-32:1 was reduced.
We identified 17 PE species that associate with mortality with
PE 36:6 being the only protective PE species (Figure 2A). The
remaining 16 PE species were positively associated with mortality,
independent of chain length and degree of saturation. They consist
of one saturated (PE 32:0), five monounsaturated (PE 30:1, 32:1,
34:1, 36:1, 40:1) and 11 polyunsaturated (PE 30:2, 34:2, 36:2,
38:2, 34:3, 36:3, 36:4, 38:4, 36:5, 38:5, 38:7) species. PE species of
the 34 C-atom series (34:1, 34:2, 34:3) revealed strongest positive
mortality association.
From the PE-ether lipid species PE O-32:0, PE O-34:1, and PE
O-36:2 showed positive mortality association (Figure 2B). For PE
O-38:7 an assocition with a protective effect was visible (Figure 2B).
Five SM species showed an association with a protective effect,
mainly saturated species with 22, 23 and 24 carbon-atoms; a slight
association with a protective effect was also visible for SM 22:1 and
23:1. In contrast, SM 16:0, 16:1, 24:1 and 24:2 displayed positive
association with mortality (Figure 3A). From the 5 identified Cer
species three displayed positive association with mortality (16:0,
18:0, 24:1); the remaining two Cer species (23:0, 24:0) were slightly
protective (Figure 3B). In summary highly polyunsaturated PC
species together with LPC species and long chain saturated SM
species seem to be associated with a protective role. PC 32:0
(probably PC 16:0/16:0) and SM 16:0 showed together with Cer
24:1 strongest positive association with mortality. Interestingly
similar tendencies were observed for 16:0, 23:0, 24:0 and 24:1 SM
and Cer species.
Finally we tested if the combination of certain lipid species
increased their prognostic value. Therefore a quotient of the six
most protective species (SM 23:0, SM 24:0, PC 38:5, PC 38:6, PC
36:5 and PC 40:6) and the six species with the strongest positive
mortality association (SM 16:0, SM 24:1, Cer 16:0, Cer 24:1, PC
32:0 and PC O-32:0) was calculated. The result of that were
hazard ratios of 2.725 (95% confidence interval: 2.350–3.160, p,
0.001) for cardivascular and 2.508 (95% confidence interval:
2.223–2.830, p,0.001) for total mortality, which is far higher than
the results for individual species. To compare the quality of the
quotient with known risk factors, like age, gender, LDL, HDL,
BMI, diabetes, hypertension, CAD and C-reactive protein (CRP),
the individual hazard ratios (unadjusted) within our cohort were
calculated (Table 2). Diabetes, CAD and age (per 10 years
increase) showed an approximately 2-fold increase; hypertension,
CRP and male sex showed an approximately 1.3-fold increase
while female sex showed a roughly 1.3-fold decrease of risk
(Table 2). LDL, HDL and BMI showed no effect (Table 2). The
quotient of the sums of protective and risk lipid species on the
other hand showed an almost 3-fold increased risk.
Discussion
In this study we provide data that plasma glycerophospholipid
and sphingolipid species are easily accessible predictors of
mortality. Identified saturated and monounsaturated PC species
are positively associated with mortality, with PC 32:0 revealing the
strongest positive association (Figure 1A). PC 32:0 most likely is
composed of two palmitates (16:0) at sn-1 and sn-2 position,
alternatively myristate (14:0) and stearate (18:0) could also form
Lipid Species and Mortality: The LURIC Study
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PC 32:0. The delta-9-desaturase (D9D) stearoyl-CoA desaturase
(SCD/FADS5/D9D) shows specific affinity for the two main
dietary saturated FAs palmitate and stearate, converting them to
the corresponding monounsaturated FAs palmitoleate (16:1n-7)
and oleate (18:1n-9) (figure 4). This indicates a protective role of
SCD as PC 32:1 and PC 32:2, containing SCD desaturation
products, compared to PC 32:0 reduce their mortality association,
with PC 32:2 being even slightly but significantly protective
(Figure 1A). This is in agreement with studies suggesting that
deregulation of SCD supports inflammation, atherosclerosis,
Figure 1. Mortality association of PC species (A), LPC species (B) and PC O species (C). EDTA plasma concentrations were determined by
ESI-MS/MS. Species with significant association to CAD and total mortality are shown. Models were adjusted for age, gender, smoking, LDL, HDL,
diabetes and hypertension. Bars represent the hazard ratio 21. Positive association with CAD is shown in grey and positive association with total
mortality in black. Negative association with CAD is shown by a dashed white bar and negative association with total mortality in white. Species are
named according to the number of carbon atoms and degree of desaturation. Besides their association the mean concentration and standard
deviation are shown. PC and LPC species were annotated based on assumption of even numbered carbon chains only.
doi:10.1371/journal.pone.0085724.g001
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hypertriglyceridemia, and metabolic syndrome [38]. Besides
SCD/FADS5/D9D, the delta-6 desaturase (D6D)/FADS2 may
also be involved, generating octadecadienate (18:2n-9) from oleate.
This effect is less pronounced for PC 36:2 and PC 38:2, although a
similar tendency is visible.
10 PC species containing long-chain PUFAs were found
associated with a protective effect in our analysis (Figure 1A).
This may reflect diet and/or physical activity of the patients, as it
was shown that e.g. fish oil supplementation increased the relative
amount of PUFA containing phospholipids and tryglycerides [39]
and that physical activity leads to higher amounts of PUFA
containing TGs [40]. These PC species probably contain FAs
originating from n-3 and/or n-6 dietary essential FAs, and their
elongation/desaturation products. Elongation/desaturation prod-
ucts of n-9 octadecadienate could also be components of these PC
species. It may be speculated that the protective effect is based on
either (i) withdrawing pro-inflammatory eicosanoids of the n-6
series from their signaling pathways or (ii) providing anti-
inflammatory eicosanoids of the n-3 series. In summary, PC
species containing long chain saturated and monounsaturated n-9
FAs positively associate with mortality while long-chain PUFAs
appeared to be associated with a protective effect. Although it is
not possible to resolve the exact FA composition of the measured
PC species with the method used here, it is highly probable that
the protective species contain arachidonic acid (20:4n-6). This is
supported by a previous study observing that an increased 20:4n-6
to 20:3n-6 ratio attends with a reduced coronary heart disease risk
[41].
Elongation steps of the n-3 and n-6 series are catalyzed by
members of the elongation of very long chain fatty acids-like
(ELOVL) family, namely ELOVL2 and ELOVL5 (figure 4).
ELOVL2 catalyzes the rate-limiting PUFA elongation steps of n-6
arachidonyl-CoA (20:4) to docosatetraenoyl-CoA (22:4), and
further to tetracosatetraenoyl-CoA (24:4) (figure 4). ELOVL2 is
also involved in the n-3 pathway to form docosapentaenoyl-CoA
(22:5) and tetracosapentaenoyl-CoA (24:5) (figure 4). Strongest
association of ELOVL2 was shown with ratios between PCs that
differ by two or four carbon atoms in their FA side chains, and that
are likely to contain a PUFA of the aforementioned type at the sn-
2 position of their glycerol backbone [15]. Desaturation is
mediated by D5D/FADS1 and D6D/FADS2. D5D/FADS1 is
required for the desaturation of 20:3n-6, 20:4n-3 and 20:2n-9 FAs,
leading to 20:4n-6, 20:5n-3 and 20:3n-9 FAs (figure 4). All
substrates and products of the D5D/FADS1 reaction are very
Figure 2. Mortality association of PE species (A) and PE O species (B). Species with significant association to CAD and total mortality are
shown. EDTA plasma concentrations were determined by ESI-MS/MS. Models were adjusted for age, gender, smoking, LDL, HDL, diabetes and
hypertension. Bars represent the hazard ratio21. Positive association with CAD is shown in grey and positive association with total mortality in black.
Negative association with CAD is shown by a dashed white bar and negative association with total mortality in white. Species are named according to
the number of carbon atoms and degree of desaturation. Besides their association the mean concentration and standard deviation are shown. PE
species were annotated based on assumption of even numbered carbon chains only.
doi:10.1371/journal.pone.0085724.g002
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likely constituents of PC 38:5. D6D/FADS2 uses 18:2n-6 and
18:1n-9 as substrates (figure 4), which also represent potential
constituents of PC 38:5. Desaturation of 18:1n-9 generates 18:2n-
9, which also could be a constituent of PC 38:5 (figure 4). The
protection-associated PC species 36:4, 38:4, 36:5 and 38:6 were
previously shown to negatively correlate with an intronic SNP
(rs174548) in the D5D/FADS1 gene, while PC 34:2, which we
found mortality associated, revealed a positive correlation with this
SNP ([16] and references therein).
LPC species originate predominantly from phospholipase A1/
A2, endothelial lipase and lecithin-cholesterol acyltransferase
(LCAT) activity [9]. Cleavage can occur at either the sn-1
(phospholipase A1) or sn-2 (phospholipase A2) position of the
glycerophospholipid. Three LPC species with mortality association
were identified (LPC 16:0, LPC 18:0 and LPC 18:2) which are all
associated with a protective effect (Figure 1B). 16:0 and 18:0 FAs
are equally found in PC species positively and negatively
associated with mortality. Recently it was shown that circulating
LPC species are reduced in obesity and that more probably diet
and adiposity than IR and diabetes are the reason for this [42].
Similar to the protection-associated PC species, the protection-
associated LPC species may reflect diet.
In contrast to PC species all identified PC O (Figure 1C), PE
and PE O (Figure 2A and B) species besides PE 36:6 and PE O
38:7 showed positive mortality association independent from chain
length and degree of saturation. Interestingly similar tendencies
were observed for 16:0, 23:0, 24:0 and 24:1 SM and Cer
(Figure 3A and B), stressing the importance of SM/Cer
conversion. SM is converted to Cer via the sphingomyelin
phosphodiesterases SMPD1-4 [43] and ectonucleotide pyrophos-
phatase/phosphodiesterase 7 (ENPP7) [44]. The sphingomyelin
Figure 3. Mortality association of SM species (A) and Cer species (B). EDTA plasma concentrations were determined by ESI-MS/MS. Species
with significant association to CAD and total mortality are shown. Models were adjusted for age, gender, smoking, LDL, HDL, diabetes and
hypertension. Bars represent the hazard ratio21. Positive association with CAD is shown in grey and positive association with total mortality in black.
Negative association with CAD is shown by a dashed white bar and negative association with total mortality in white. Species are named according to
the number of carbon atoms and degree of desaturation. Besides their association the mean concentration and standard deviation are shown
together with the putative involved Cer-synthase. SM species annotation is based on the assumption that d18:1 (dihydroxy 18:1 sphingosine) is the
main base of plasma SM species.
doi:10.1371/journal.pone.0085724.g003
Table 2. Comparison of hazards ratios of the quotient of the
sums of the protective and risk lipid species with known
cardiovascular risk factors.
Risk factor p-value HR 95% CI
Lipid ratio (per 0.1 unit increase) ,0.001 2.886 2.580 – 3.227
Age (per 1 year increase) ,0.001 1.070 1.061 – 1.078
Age (per 10 year increase) ,0.001 1.972 1.821 – 2.135
Female gender 0.004 0.789 0.672 – 0.927
Male gender 0.004 1.267 1.078 – 1.488
LDL cholesterol 0.042 0.998 0.995 – 0.999
HDL cholesterol ,0.001 0.982 0.974 – 0.988
BMI 0.009 0.976 0.958 – 0.994
Diabetes ,0.001 2.273 1.973 – 2.618
Hypertension ,0.001 1.387 1.168 – 1.646
CAD (. = 20% stenosis) ,0.001 2.220 1.787 – 2.757
CAD (. = 50% stenosis) ,0.001 2.031 1.697 – 2.429
lnCRP ,0.001 1.304 1.237 – 1.372
BMI, body mass index; CAD, coronary artery disease; CI, confidence interval;
CRP, C-reactive protein; HDL, high density lipoprotein; HR, hazard ratio; LDL, low
density lipoprotein.
doi:10.1371/journal.pone.0085724.t002
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synthases SGMS1-2 are capable of catalyzing both, the conversion
SM to Cer and Cer to SM {Huitema, 2004 4513/id}. The
mortality associated Cer species 16:0 and 24:1 together with the
protection-associated Cer 23:0 and Cer 24:0 were shown to
correlate with a SNP (rs680379) upstream the SPTLC3 gene [14].
While Cer 16:0 revealed negative correlation with SPTLC3 the
longer Cer species showed a positive correlation [14]. From the 9
SM species identified in this work 5 were shown to correlate with
SNPs in the SGPP1 region [14].
The observed hazard ratios of 2.725 (95% confidence interval:
2.350–3.160, P,0.001) for cardivascular and 2.508 (95% confi-
dence interval: 2.223–2.830, P,0.001) for total mortality were
achieved using a quotient of the sums of the six most protective
species (SM 23:0, SM 24:0, PC 38:5, PC 38:6, PC 36:5 and PC
40:6) and the sums of the six species with the strongest positive
mortality association (SM 16:0, SM 24:1, Cer 16:0, Cer 24:1, PC
32:0 and PC O-32:0). They are independent of the known
cardiovascular risk factors age, gender, smoking, LDL, HDL,
diabetes and hypertension. In comparison the quotient of
protective and risk lipid species had an even better prognostic
value than the known risk factors in our cohort (Table 2). The
surprising result that LDL did not affect the risk of cardiovascular
mortality is probably an effect of LDL lowering therapy.
In summary the data presented here indicate together with
previously published SNP lipid species-correlations that SNPs in
lipid metabolism related gene-region influence lipid species levels
and mortality. Moreover, the quotient of the sums of the six most
protective species and the six species with the strongest positive
mortality association may be a valuable prognostic marker, which
has to be confirmed in independent cohorts.
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